Pharmaceutical - Respiratory and Pulmonary, Financial

Filter

Popular Filters

1 to 25 of 35 results

AstraZeneca reinforces target of $45 billion revenues by 2023

AstraZeneca reinforces target of $45 billion revenues by 2023

18-11-2014

Anglo-Swedish pharma major AstraZeneca today provided an update for institutional investors and financial…

AstraZenecaCardio-vascularFinancialInflammatory diseasesMetabolicsOncologyPharmaceuticalRespiratory and PulmonaryUK

ALK Abello reports positive financials for third quarter with sales up 3%

ALK Abello reports positive financials for third quarter with sales up 3%

14-11-2014

Denmark-based allergy specialist ALK Abello has reported positive results for the third quarter of 2014.

ALK AbelloDenmarkFinancialGrazaxPharmaceuticalRespiratory and Pulmonary

GlaxoSmithKline invests in Australia plant expansion

14-11-2014

UK pharma major GlaxoSmithKline’s Australian subsidiary today announced it will be investing A$31 million…

AustraliaFinancialGlaxoSmithKlinePharmaceuticalProductionRespiratory and PulmonaryVentolin HFA

Vectura gets VR315 US development milestone

07-11-2014

UK inhaled therapies developer Vectura Group says that it has triggered a further milestone associated…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVectura GroupVR315

Allergy Therapeutics shows increase in revenue in preliminary results

Allergy Therapeutics shows increase in revenue in preliminary results

22-09-2014

UK-based Allergy Therapeutics has announced its preliminary results for the year ended June 30, 2014,…

Allergy TherapeuticsFinancialPharmaceuticalPollinex QuattroRespiratory and PulmonaryUK

ALK Abello reports strong improvement in 2nd-qtr financials

ALK Abello reports strong improvement in 2nd-qtr financials

13-08-2014

Denmark-based allergy specialist ALK Abello has reported significant progress in its sales for the second…

ALK AbelloDenmarkFinanceFinancialNorwegian kronePharmaceuticalRespiratory and Pulmonary

Vectura earns VR315 US development milestone

24-06-2014

UK developer of inhaled therapies Vectura Group says that it has triggered a milestone of $1.5 million…

FinancialPharmaceuticalResearchRespiratory and PulmonaryVecturaVR315

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

GlaxoSmithKline in $105 million settlement for mis-selling with 44 US states

05-06-2014

UK pharma giant GlaxoSmithKline has agreed to a $105 million settlement with 44 US states and the District…

AdvairFinancialGlaxoSmithKlineLegalMarkets & MarketingNeurologicalPaxilPharmaceuticalRespiratory and PulmonaryUSAWellbutrin

Vectura sees hefty rise in full-year 2013/14 revenues, as loss narrows

21-05-2014

Shares of UK developer of inhaled therapies Vectura gained 3.1% to 131.45 pence in early trading this…

FinancialPharmaceuticalRespiratory and PulmonaryVectura

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

Vectura to buy Germany’s Activaero for 130 million euros

Vectura to buy Germany’s Activaero for 130 million euros

14-03-2014

UK developer of inhaled therapies Vectura says it is acquiring privately-held German company Activaero…

ActivaeroFinancialMergers & AcquisitionsPharmaceuticalRespiratory and PulmonaryVectura

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

Return to growth: AstraZeneca’s CEO Pascal Soriot says 2013 was year of “momentum” for the company

06-02-2014

‘Momentum’ is the word which best describes 2013, according to AstraZeneca’s chief executive Pascal…

AstraZenecaBrilintaCardio-vascularCrestorDiabetesExenatide InjectionFinancialInterviewsNexiumOncologyPharmaceuticalRespiratory and PulmonarySymbicortUK

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

Forest reports third quarter sales of $846.8 million beating analysts’ expectations

21-01-2014

US drugmaker Forest Laboratories (NYSE: FRX) released its third quarter 2013/14 results today showing…

CNS DiseasesFinancialForest LaboratoriesPharmaceuticalRespiratory and PulmonaryUSA

New UK pharma company to target respiratory disease

New UK pharma company to target respiratory disease

11-12-2013

A new biopharmaceutical company has been founded to develop innovative new approaches to treat respiratory…

FinancialPharmaceuticalRespiratory and PulmonaryUK

Vectura posts flat sales and increased loss for first-half 2013

19-11-2013

UK-based developer of inhaled therapies Vectura Group has announced its unaudited interim results for…

FinancialNovartisPharmaceuticalRespiratory and PulmonaryVectura

Theravance and GSK launch Breo Ellipta in USA

Theravance and GSK launch Breo Ellipta in USA

30-10-2013

GlaxoSmithKline and US partner Theravance today announced that Breo Ellipta for COPD is available to…

Breo ElliptaFinancialGlaxoSmithKlineMarkets & MarketingNorth AmericaPharmaceuticalRespiratory and PulmonaryTheravance

Forest Labs reports rise in sales and EPS doubles in second quarter results

23-10-2013

Forest Laboratories has released its second quarter results which showed that net sales for the quarter…

BystolicCNS DiseasesDalirespFinancialForest LaboratoriesLinzessNamendaNorth AmericaPharmaceuticalRespiratory and PulmonarySavellaTeflaroTudorza PressairViibryd

Analysts recommend GSK after Teva announces Advair generic delay

Analysts recommend GSK after Teva announces Advair generic delay

11-10-2013

The delay for the generic version of GlaxoSmithKline’s Advair coupled with the advances in the company’s…

AdvairdarapladibEuropeFinancialGlaxoSmithKlineNeurologicalPharmaceuticalRespiratory and PulmonaryTeva Pharmaceutical Industries

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

Vectura foresees important catalysts in second half

13-08-2013

Shares of UK-based developer of inhaled therapies Vectura (LSE: VEC) rose 1.6% to 96 pence in mid-morning…

EuropeFinancialPharmaceuticalRespiratory and PulmonarySeebri BreezhalerUltibro BreezhalerVectura

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

Merck & Co opens new $120 million manufacturing plant in China

19-04-2013

US Pharma giant Merck & Co (NYSE: MRK) has opened its new pharmaceutical manufacturing facility in Hangzhou,…

Asia-PacificCardio-vascularDiabetesFinancialMerck & CoPharmaceuticalProductionRespiratory and Pulmonary

Briefs: Sanofi to up stake in Regeneron; Bayer files for riociguat approval

12-02-2013

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) saw its shares rise 4.8% to $173.84 in early trading…

BayerBiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegeneronRegulationRespiratory and PulmonaryriociguatSanofi

1 to 25 of 35 results

Back to top